Filing Flows › Silence Therapeutics (SLN) › Q1 2026 › vs Q1 2025
Silence Therapeutics (SLN) Q1 2026 vs Q1 2025 (year over year)
Silence Therapeutics's revenue rose $280K (+197%) from $142K in Q1 2025 to $422K in Q1 2026.
Silence Therapeutics, Q1 2026: revenue $422K (+197% year over year), net loss $15.0M, operating cash flow −$15.6M. The chart draws each line against Q1 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q1 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $422K | $142K | $280K | +197% |
| Other income, net | $780K | −$121K | $901K | — |
| Net loss | $15.0M | $28.5M | −$13.6M | -48% |
| Costs & expenses | $16.2M | $28.7M | −$12.5M | -44% |
| Operating costs | $16.2M | $28.6M | −$12.4M | -43% |
| Cost of revenue | $11K | $54K | −$43K | -80% |
| Research & development | $9.1M | $20.8M | −$11.7M | -56% |
| General & admin | $7.0M | $7.7M | −$658K | -9% |
| Operating cash sources | $18.1M | $15.9M | $2.2M | +14% |
| Depreciation | $72K | $73K | −$1K | -1% |
| Share-based compensation | $2.4M | $3.5M | −$1.1M | -31% |
| Cash used in operations | $15.6M | $12.3M | $3.3M | +27% |
| Net loss absorbed | $15.0M | $28.5M | −$13.6M | -48% |
| Working capital & other | $3.2M | −$12.6M | $15.8M | — |
Questions
How much did Silence Therapeutics's revenue grow year over year in Q1 2026?
Silence Therapeutics's revenue rose $280K (+197%) from $142K in Q1 2025 to $422K in Q1 2026.